Targeted Treatment Slowed Disease Progression in Studies
http://www.webmd.com/cancer/pancreatic-cancer/news/20110208/2-drugs-look-promising-for-rare-pancreatic-cancer"Two kidney cancer drugs show promise for the treatment of the rare type of pancreatic cancer that Apple CEO Steve Jobs was diagnosed with in 2004.
In studies to be published tomorrow in the New England Journal of Medicine, researchers report that the targeted therapies dramatically improved disease-free survival times in patients with pancreatic neuroendocrine tumors.
One of the phase III trials, involving Pfizer’s drug Sutent, was stopped early because the drug proved to be so effective.
In the other study, one out of three patients who took Novartis’ drug Afinitor had no evidence of tumor growth during 18 months of treatment, compared to one in 10 placebo-treated patients.
..."--------------------------
Preliminary, yes. But good news!